RxDoctor Payments Data

Devan Makati, MD

Internal Medicine · Morgantown, WVNPI 1063877249

Payments from drug & device makers

$1,238in general payments, 2019–2025

Across 21 payments — averaging $58.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$874
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$153
  • Nxstage Medical, Inc.$132
  • Bayer$60
  • Alnylam Pharmaceuticals Inc.$17
  • Travere Therapeutics, Inc.$2

What the payments were for

  • Speaking & faculty fees$40032%
  • Food & beverage$81866%
  • Education$202%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,238 in reported general payments places this provider in the 75th percentile of 573 internal medicine providers in West Virginia.

See all internal medicine providers in West Virginia

Medicare billing

Part B allowed, 2024
$99,930
Medicare patients
316
Services billed
934

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol41$67,088
JardianceEmpagliflozin38$62,373
VeltassaPatiromer Calcium Sorbitex11$16,500
ClinisolParenteral Amino Acid 15% No.549$6,031
Nifedipine ErNifedipine158$3,235
Torsemide100$2,013
Calcium Acetate24$1,486
Famotidine77$1,153
Chlorthalidone85$1,104
ProsolParenteral Amino Acid 20% No.111$1,003
Tamsulosin Hcl91$994
Ezetimibe65$840
Losartan Potassium105$824
Isosorbide Mononitrate ErIsosorbide Mononitrate61$712
Carvedilol96$548

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$874$67,08841 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 573 internal medicine providers in West Virginia.

Other internal medicine in Morgantown

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →